Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
Vladimir А. Gushchin, Inna V. Dolzhikova, А. М. Щетинин, et al.
Vaccines (2021) Vol. 9, Iss. 7, pp. 779-779
Open Access | Times Cited: 114

Showing 1-25 of 114 citing articles:

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
SARS-COV-2 Variants: Differences and Potential of Immune Evasion
Sandro Massao Hirabara, Tamires Duarte Afonso Serdan, Renata Gorjão, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 11
Open Access | Times Cited: 206
SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines
Suresh Thakur, Shalitha Sasi, Sindhu Gopinathan Pillai, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 133
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Mekonnen, et al.
Seminars in Immunology (2021) Vol. 55, pp. 101533-101533
Open Access | Times Cited: 105
Two Years into the COVID-19 Pandemic: Lessons Learned
Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 9, pp. 1758-1814
Open Access | Times Cited: 103
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
V. Edwin Hillary, Stanislaus Antony Ceasar
Heliyon (2023) Vol. 9, Iss. 3, pp. e13952-e13952
Open Access | Times Cited: 76
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
А. И. Тухватулин, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, et al.
The Lancet Regional Health - Europe (2021) Vol. 11, pp. 100241-100241
Open Access | Times Cited: 64
Controversy surrounding the Sputnik V vaccine
Mario Cazzola, Paola Rogliani, Filomena Mazzeo, et al.
Respiratory Medicine (2021) Vol. 187, pp. 106569-106569
Open Access | Times Cited: 60
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Jingbo Qian, Shi-Chang Zhang, Fang Wang, et al.
Cell Biology International (2024) Vol. 48, Iss. 4, pp. 404-430
Open Access | Times Cited: 12
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 9
Covid-19: How many variants are there, and what do we know about them?: Video 1
Elisabeth Mahase
BMJ (2021), pp. n1971-n1971
Closed Access | Times Cited: 44
Snake venom phospholipase A2s exhibit strong virucidal activity against SARS-CoV-2 and inhibit the viral spike glycoprotein interaction with ACE2
Andrei E. Siniavin, Maria A. Streltsova, Maria A. Nikiforova, et al.
Cellular and Molecular Life Sciences (2021) Vol. 78, Iss. 23, pp. 7777-7794
Open Access | Times Cited: 41
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
I. A. FAVORSKAYA, Dmitry V. Shcheblyakov, I. B. Esmagambetov, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 33
Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
SubbaRao V. Tulimilli, Siva Dallavalasa, Chaithanya G. Basavaraju, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1751-1751
Open Access | Times Cited: 28
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Armina Alagheband Bahrami, Ali Azargoonjahromi, Samin Sadraei, et al.
Cellular & Molecular Biology Letters (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 27
Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance
А. С. Шкода, Vladimir А. Gushchin, Darya A. Ogarkova, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 938-938
Open Access | Times Cited: 27
Analysis of the immune response in COVID-19
Altijana Hromić‐Jahjefendić, Alaa A. A. Aljabali
Progress in molecular biology and translational science (2025)
Closed Access
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity
Jitendra Kumar Chaudhary, Rohitash Yadav, Pankaj Kumar Chaudhary, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 2949-2949
Open Access | Times Cited: 35
Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina
Rossana Elena Chahla, Rodrigo Hernán Tomas‐Grau, Silvia I. Cazorla, et al.
The Lancet Regional Health - Americas (2021) Vol. 6, pp. 100123-100123
Open Access | Times Cited: 32
An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight
Shoaib Shoaib, Mohammad Azam Ansari, Geetha Kandasamy, et al.
Molecules (2023) Vol. 28, Iss. 2, pp. 795-795
Open Access | Times Cited: 12
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Franziska Günl, Angeles Mecate‐Zambrano, Selina Rehländer, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1052-1052
Open Access | Times Cited: 28
Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation
Maria G. Byazrova, Sergey V. Kulemzin, Ekaterina A. Astakhova, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
Mitch Brinkkemper, Tim S. Veth, Philip J. M. Brouwer, et al.
iScience (2022) Vol. 25, Iss. 12, pp. 105649-105649
Open Access | Times Cited: 19
Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy
Vladimir А. Gushchin, Е. В. Цыганова, Darya A. Ogarkova, et al.
EClinicalMedicine (2022) Vol. 46, pp. 101360-101360
Open Access | Times Cited: 18
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
Ramesh Kandimalla, Pratik Chakraborty, V. Jayalakshmi, et al.
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1740-1740
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top